Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eupraxia Pharmaceuticals Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
EPRX
Nasdaq
2836
www.eupraxiapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eupraxia Pharmaceuticals Inc.
Eupraxia's DiffuSphereâ„¢ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
- Nov 20th, 2024 12:00 pm
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
- Nov 14th, 2024 10:00 pm
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
- Nov 13th, 2024 10:00 pm
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Nov 12th, 2024 10:56 pm
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
- Nov 7th, 2024 10:00 pm
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
- Oct 31st, 2024 11:36 pm
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
- Oct 28th, 2024 11:00 am
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
- Oct 15th, 2024 11:00 am
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
- Oct 10th, 2024 11:00 am
Eupraxia Pharmaceuticals Strengthens Senior Management Team
- Oct 2nd, 2024 9:01 pm
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
- Sep 19th, 2024 9:00 pm
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Sep 11th, 2024 11:00 am
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 4th, 2024 11:00 am
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
- Aug 7th, 2024 9:00 pm
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
- Aug 2nd, 2024 11:00 am
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
- Jul 8th, 2024 11:00 am
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
- Jul 3rd, 2024 9:00 pm
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
- Jun 6th, 2024 9:00 pm
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
- Jun 5th, 2024 11:00 am
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- May 23rd, 2024 9:00 pm
Scroll